.

Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

McKinsey
Express Scripts
Baxter
AstraZeneca
US Army
QuintilesIMS
UBS
Johnson and Johnson
Citi
Dow

Generated: September 19, 2017

DrugPatentWatch Database Preview

DEPO-SUBQ PROVERA 104 Drug Profile

« Back to Dashboard

What is the patent landscape for Depo-subq Provera 104, and what generic Depo-subq Provera 104 alternatives are available?

Depo-subq Provera 104 is a drug marketed by Pharmacia And Upjohn and is included in one NDA. There is one patent protecting this drug.

This drug has forty patent family members in twenty-nine countries.

The generic ingredient in DEPO-SUBQ PROVERA 104 is medroxyprogesterone acetate. There are nineteen drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the medroxyprogesterone acetate profile page.

Summary for Tradename: DEPO-SUBQ PROVERA 104

Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list41
Clinical Trials: see list409
Patent Applications: see list7,137
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:DEPO-SUBQ PROVERA 104 at DailyMed

Pharmacology for Tradename: DEPO-SUBQ PROVERA 104

Ingredient-typeProgesterone Congeners
Drug ClassProgestin
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pharmacia And Upjohn
DEPO-SUBQ PROVERA 104
medroxyprogesterone acetate
INJECTABLE;SUBCUTANEOUS021583-001Dec 17, 2004RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: DEPO-SUBQ PROVERA 104

Country Document Number Estimated Expiration
Japan4205341► Subscribe
Australia2001267371► Subscribe
Hungary0302021► Subscribe
Poland365793► Subscribe
Spain2254443► Subscribe
Germany60116084► Subscribe
Israel165888► Subscribe
Hong Kong1054194► Subscribe
Estonia200200631► Subscribe
Japan2003533467► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: DEPO-SUBQ PROVERA 104

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0037Belgium► SubscribePRODUCT NAME: OESTROGENES EQUINS CONJUGUES; ACETATE DE MEDROXYPROGESTERONE; NAT. REGISTRATION NO/DATE: NL 19569 19950301; FIRST REGISTRATION: CH - 52647 01 010 19940826
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Mallinckrodt
Cantor Fitzgerald
Cerilliant
AstraZeneca
McKesson
Healthtrust
Johnson and Johnson
McKinsey
US Department of Justice
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot